Thyroid Cancer Survivorship Management

  • Sherrie L. Flores
  • Mouhammed Amir Habra
Part of the MD Anderson Cancer Care Series book series (MDCCS)


Thyroid cancer survivors enjoy long life expectancy but may experience lifelong complications attributable to surgery, radioactive iodine therapy, or thyroid hormone suppression. The importance of these potential complications increases over time as the active initial cancer therapy is completed and the acute threat of the malignancy ebbs. Accordingly, a comprehensive examination of individuals treated for thyroid cancer should be undertaken as soon as possible to detect and correct problems and to improve quality of life in these patients. The Thyroid Cancer Survivorship Clinic at MD Anderson has been developed to provide an environment in which thyroid cancer survivors can be evaluated and potential future effects of cancer and cancer therapy can be addressed. In addition, providing this service can facilitate development of evidence-based guidelines for treatment goals and long-term surveillance


Thyroid Cancer Recurrent Laryngeal Nerve Differentiate Thyroid Carcinoma Grave Ophthalmopathy Central Neck Dissection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Suggested Readings

  1. Biondi B, Palmieri EA, Lombardi G, et al. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002;137(11):904–914.PubMedCrossRefGoogle Scholar
  2. Bomeli SR, Schaitkin B, Carrau RL, et al. Interventional sialendoscopy for treatment of radioiodine-induced sialadenitis. Laryngoscope 2009;119(5):864–867.PubMedCrossRefGoogle Scholar
  3. Ceccarelli C, Bencivelli W, Morciano D, et al. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab 2001;86(8):3512–3515.PubMedCrossRefGoogle Scholar
  4. Esfahani AF, Eftekhari M, Zenooz N, Saghari M. Gonadal function in patients with differentiated thyroid cancer treated with (131)I. Hell J Nucl Med 2004;7(1):52–55.PubMedGoogle Scholar
  5. Fard-Esfahani A, Mirshekarpour H, Saghari M, et al. The effect of high-dose radioiodine treatment on lacrimal gland function in patients with differentiated thyroid carcinoma. Clin Nucl Med 2007;32(9):696–699.PubMedCrossRefGoogle Scholar
  6. Gammage MD, Parle JV, Holder RL, et al. Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 2007;167(9):928–934.PubMedCrossRefGoogle Scholar
  7. Grewal RK, Larson SM, Pentlow CE, et al. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation. J Nucl Med 2009;50(10):1605–1610.PubMedCrossRefGoogle Scholar
  8. Hartl DM, Travagli JP, Leboulleux S, et al. Clinical review: current concepts in the management of unilateral recurrent laryngeal nerve paralysis after thyroid surgery. J Clin Endocrinol Metab 2005;90(5):3084–3088.PubMedCrossRefGoogle Scholar
  9. Hoftijzer HC, Heemstra KA, Corssmit EP, van der Klaauw AA, Romijn JA, Smit JW. Quality of life in cured patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008;93(1):200–203.PubMedCrossRefGoogle Scholar
  10. Hyer S, Kong A, Pratt B, et al. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol 2007;19(1):83–86.CrossRefGoogle Scholar
  11. Hyer S, Vini L, O’Connell M, et al. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol 2002;56(6):755–758.CrossRefGoogle Scholar
  12. Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011;117(19):4439–4446.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Joffe RT, Brimacombe M, Levitt AJ, et al. Treatment of clinical hypothyroidism with thyroxine and triiodothyronine: a literature review and metaanalysis. Psychosomatics 2007;48(5):379–384.PubMedCrossRefGoogle Scholar
  14. Lee JS, Buzkova P, Fink HA, et al. Subclinical thyroid dysfunction and incident hip fracture in older adults. Arch Intern Med 2010;170(21):1876–1883.PubMedCrossRefPubMedCentralGoogle Scholar
  15. Ma C, Xie J, Jiang Z, et al. Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 2010;37(9):1778–1785.PubMedCrossRefGoogle Scholar
  16. Nakada K, Ishibashi T, Takei T, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 2005;46(2):261–266.PubMedGoogle Scholar
  17. Paul TL, Kerrigan J, Kelly AM, Braverman LE, Baran DT. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988;259(21):3137–3141.PubMedCrossRefGoogle Scholar
  18. Reverter JL, Colome E, Holgado S, et al. Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma. Endocrine 2010;37(3):467–472.PubMedCrossRefGoogle Scholar
  19. Rosenbaum MA, McHenry CR. Central neck dissection for papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2009;135(11):1092–1097.PubMedCrossRefGoogle Scholar
  20. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancies in thyroid cancer patients. Brit J Cancer 2003;89(9):1638–1644.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. New Engl J Med 1994;331(19):1249–1252.PubMedCrossRefGoogle Scholar
  22. Sawka AM, Thabane L, Parlea L, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009;19(5):451–457.PubMedCrossRefGoogle Scholar
  23. Schultz PN, Stava C, Vassilopoulou-Sellin R. Health profiles and quality of life of 518 survivors of thyroid cancer. Head & Neck 2003;25(5):349–356.CrossRefGoogle Scholar
  24. Sgarbi JA, Villaca FG, Garbeline B, et al. The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. J Clin Endocrinol Metab 2003;88(4):1672–1677.PubMedCrossRefGoogle Scholar
  25. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63(1):11–30.PubMedCrossRefGoogle Scholar
  26. Silberstein EB. Reducing the incidence of 131I-induced sialadenitis: the role of pilocarpine. J Nucl Med 2008;49(4):546–549.PubMedCrossRefGoogle Scholar
  27. Singh S, Duggal J, Molnar J, et al. Impact of subclinical thyroid disorders on coronary heart disease, cardiovascular and all-cause mortality: a meta-analysis. International J Cardiol 2008;125(1):41–48.CrossRefGoogle Scholar
  28. Tan LG, Nan L, Thumboo J, Sundram F, Tan LK. Health-related quality of life in thyroid cancer survivors. Laryngoscope 2007;117(3):507–510.PubMedCrossRefGoogle Scholar
  29. Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996;81(12):4278–4289.PubMedGoogle Scholar
  30. van Wilgen CP, Dijkstra PU, van der Laan BF, et al. Shoulder and neck morbidity in quality of life after surgery for head and neck cancer. Head & Neck 2004;26(10):839–844.CrossRefGoogle Scholar
  31. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C. Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. Postgraduate Medical Journal 2002;78(916):92–93.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© The University of Texas M. D. Anderson Cancer Center 2015

Authors and Affiliations

  • Sherrie L. Flores
    • 1
  • Mouhammed Amir Habra
    • 1
  1. 1.Department of Endocrine Neoplasia and Hormonal DisordersThe University of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations